Replimune Group, Inc. (REPL) Competitors & Peers
The 5 largest companies in the same industry as Replimune Group, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $508.34 | P/E 29.6RSI 45Cap 128.8 B |
| REGN | Partner | $784.85 | P/E 19.4RSI 48Cap 80.8 B |
| ARGX | Peer | $990.32 | P/E 38.0RSI 53Cap 62.1 B |
| RVMD | Peer | $190.95 | RSI 36Cap 40.9 B |
| CSLLY | Peer | $31.12 | P/E 18.2RSI 71Cap 60.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- TMOSupplier
Thermo Fisher supplies biological bioreactors, cell culture media, and lab single-use systems to Replimune's manufacturing facilities.
Model-inferred, unverified — treat as a lead, not evidence - BMYPartner
Collaborates on clinical combination trials pairing Replimune's RP1 with BMS's Opdivo (nivolumab).
Model-inferred, unverified — treat as a lead, not evidence - REGNPartner
Collaborates on clinical trials combining RP1 with Regeneron's PD-1 inhibitor Libtayo (cemiplimab).
Model-inferred, unverified — treat as a lead, not evidence - AMGNCompetitor
Competes in oncolytic immunotherapy; Amgen manufactures Imlygic (talimogene laherparepvec).
Model-inferred, unverified — treat as a lead, not evidence